Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity

European Urology
Delphine Behr-RousselPierre Denys

Abstract

Two botulinum toxins A have been evaluated for the treatment of refractory neurogenic detrusor overactivity (NDO) in humans: Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA). However, these two distinct commercialized products have different potency units and are not interchangeable. Assessment of the dose response and determination of minimal effective dose (MED) for Dysport and Botox in spinal cord-injured (SCI) rats with NDO. Female, adult, Sprague-Dawley rats (n=98) underwent T8-T9 spinal cord transection. Nineteen days after spinal cord injury, rats received intradetrusor injections (25μl injected, eight sites) of vehicle (V); Dysport 2, 5, 7.5, 10, and 12.5 U; and Botox 0.8, 2, 5, 7.5, and 10 U. Two days after injection, continuous cystometry was performed in conscious rats. Voiding contractions (VC) were assessed by duration of VC, intercontraction interval, voided volume, maximal pressure, pressure threshold change, and intravesical baseline pressure (BP), while nonvoiding contractions (NVC) were evaluated by amplitude, frequency, and volume threshold to elicit NVC. MEDs for Dysport and Botox were determined by analysis of variance step-down trend test. MEDs for Dysport and Botox were 10 U and 7.5 U, respecti...Continue Reading

References

Nov 24, 1999·Urology·M YoshiyamaM B Chancellor
Apr 11, 2003·The Journal of Urology·Christopher P SmithGeorge T Somogyi
Jul 2, 2003·Brain Research Bulletin·Christopher P SmithGeorge T Somogyi
Sep 1, 2004·Neurochemistry International·Mohit KheraChristopher P Smith
Sep 28, 2005·Bone·Sarah E WarnerTed S Gross
Jul 20, 2007·Journal of Clinical Pharmacy and Therapeutics·R WenzelJ A Borrego
Jan 12, 2008·Neurochemistry International·Christopher P SmithGeorge T Somogyi
Jun 23, 2009·The Journal of Urology·Yao-Chi ChuangMichael B Chancellor
Sep 22, 2009·The Journal of Urology·Kazuyoshi IijimaStefan De Wachter
Dec 22, 2009·Neurourology and Urodynamics·William C de Groat, Naoki Yoshimura
Apr 22, 2011·Neurourology and Urodynamics·Alvaro MunozChristopher P Smith

❮ Previous
Next ❯

Citations

Nov 5, 2013·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·R CaremelG Karsenty
Sep 24, 2015·International Journal of Urology : Official Journal of the Japanese Urological Association·Benoit PeyronnetXavier Gamé
Apr 22, 2017·Neurourology and Urodynamics·Florie BottetUNKNOWN Groupe d'Etude de Neuro-Urologie de Langue Française (GENULF) and the committee of NeuroUrology of the French Association of
Aug 2, 2017·International Urogynecology Journal·Andrzej WróbelTomasz Rechberger
Aug 15, 2018·Expert Opinion on Biological Therapy·Richard FlintLinda Cardozo
Oct 27, 2016·Female Pelvic Medicine & Reconstructive Surgery·Alexis A DieterMatthew O Fraser
Jun 30, 2018·Current Neurology and Neuroscience Reports·Jure Tornic, Jalesh N Panicker
Mar 11, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Andrzej WróbelEwa Poleszak
Dec 7, 2013·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Stephanie Oger-RousselFrancois Giuliano
Mar 22, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Andrzej WróbelEwa Poleszak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.